Multiple System Atrophy clinical trials at UCLA
4 in progress, 3 open to eligible people
North American Prodromal Synucleinopathy Consortium Stage 2
open to eligible people ages 18 years and up
This study will enroll participants with idiopathic REM sleep behavior disorder (RBD) and healthy controls for the purpose of preparing for a clinical trial of neuroprotective treatments against synucleinopathies.
Los Angeles, California and other locations
ONO-2808 in Patients With Multiple System Atrophy
open to eligible people ages 30-80
This is a Phase 2, double-blind, parallel-group, placebo-controlled study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of multiple doses of ONO-2808 in patients with MSA. This is the first study of ONO-2808 in patients with MSA.
Los Angeles, California and other locations
Parkinson's and Zoledronic Acid
open to eligible people ages 60 years and up
This home-based study is a randomized (1:1) placebo-controlled trial of a single infusion of zoledronic acid-5 mg (ZA) for the prevention of fractures in men and women aged 60 years and older with Parkinson's disease and parkinsonism with at least 2 years of follow-up. A total of 3500 participants will be enrolled and randomized in the United States. Participants, follow-up outcome assessors, and study investigators will be blinded to assigned study treatment. This trial is funded by the National Institute of Aging.
Los Angeles, California and other locations
North American Prodromal Synucleinopathy Consortium
Sorry, accepting new patients by invitation only
This study will enroll participants with idiopathic rapid eye movement (REM) sleep behavior disorder (RBD), for the purpose of preparing for a clinical trial of neuroprotective treatments against synucleinopathies.
Los Angeles, California and other locations
Our lead scientists for Multiple System Atrophy research studies include Susan Perlman Alon Avidan, MD, MPH.
Last updated: